Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.39 |
| ▸ | GAA | P10253 | 6/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31015530 | 0.72 | LMNA (0.47) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL29743310 | 0.72 | ALDH1A1 (0.44) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL17184963 | 0.72 | ALDH1A1 (0.44) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL22064867 | 0.71 | L3MBTL1 (0.40) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL16011597 | 0.71 | S1PR3 (0.37) | GAAL3MBTL1 | |
| SCHEMBL16533583 | 0.69 | — | — | |
| SCHEMBL11868268 | 0.68 | LMNA (0.47) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL2600116 | 0.67 | ALDH1A1 (0.46) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL23214128 | 0.67 | ABHD6 (0.33) | GAA | |
| SCHEMBL13354846 | 0.67 | CYP3A4 (0.39) | KMT2AALDH1A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| WO-2015161011-A1 | BENZAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | LMNA 3137/4885KMT2A 208/4885ALDH1A1 205/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | LMNA 3137/4885KMT2A 208/4885ALDH1A1 205/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | LMNA 3137/4885KMT2A 208/4885ALDH1A1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.